Use of an FPT inhibitor and an inhibitor of Ras Signalling Pathway to induce cancer cell death and Tumor regression

摘要

Refers to the use of a Farnesyl Transferase inhibitor such as tricyclic FPT benzocicloheptapiridina FUSED Ring of formula I, 14 mg / day to 400 mg / day; (b) an inhibitor of Ras Signalling pathway as an additional kinase inhibitor protein, an inhibitor of MEK.An inhibitor of growth factor receptor Tyrosine Kinase Inhibitor (a as an inhibitor of the ErbB2 receptor; receptor antagonist of platelet derived growth factor PDGF; an inhibitor of IGF Receptor, a tyrosine kinase inhibitor of the epidermal growth factor receptor, EGFAntibody directed against the Antibody directed against the extracellular domain of a growth factor receptor); using a quantity of 1 mg / day to 350 mg / dayAdministered simultaneously or in sequence; (c) a chemotherapeutic Agent as chlormethine, cyclophosphamide, ifosfamide, Melphalan, chlorambucil, pipobroman, triethylene melamineTrietilenofosforamina, Busulfan, carmustine, Lomustine, streptozocina, dacarbazine, temozolomide, antimetabolites, methotrexate, 5-fluorouracil, fudr, cytarabine, 6-mercaptopurine,Among others; d) radiation. The combination produces a synergistic level to produce the death of cancer cells is useful for the treatment of Lung Cancer, Pancreatic Cancer